Search Results - "Purev, Enkhtsetseg"

Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells by Ye, Haobin, Adane, Biniam, Khan, Nabilah, Alexeev, Erica, Nusbacher, Nichole, Minhajuddin, Mohammad, Stevens, Brett M., Winters, Amanda C., Lin, Xi, Ashton, John M., Purev, Enkhtsetseg, Xing, Lianping, Pollyea, Daniel A., Lozupone, Catherine A., Serkova, Natalie J., Colgan, Sean P., Jordan, Craig T.

“…From an organismal perspective, cancer cell populations can be considered analogous to parasites that compete with the host for essential systemic resources…”
Get full text

Letermovir prophylaxis through day 100 post transplant is safe and effective compared with alternative CMV prophylaxis strategies following adult cord blood and haploidentical cord blood transplantation by Sharma, Prashant, Gakhar, Neel, MacDonald, Jennifer, Abidi, Maheen Z., Benamu, Esther, Bajrovic, Valida, Purev, Enkhtsetseg, Haverkos, Bradley M., Tobin, Jennifer, Kaiser, Jeff, Chase, Stephanie, Miller, Matthew, Weinberg, Adriana, Gutman, Jonathan A.

“…We compared CMV outcomes of three prophylactic approaches used for CBT and haploidentical cord transplants from December 2009 through 2018: letermovir ( n  =…”
Get full text

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia by Winters, Amanda C., Gutman, Jonathan A., Purev, Enkhtsetseg, Nakic, Molly, Tobin, Jennifer, Chase, Stephanie, Kaiser, Jeff, Lyle, Lindsey, Boggs, Chelsey, Halsema, Keri, Schowinsky, Jeffrey T., Rosser, Julie, Ewalt, Mark D., Siegele, Bradford, Rana, Vishal, Schuster, Steven, Abbott, Diana, Stevens, Brett M., Jordan, Craig T., Smith, Clayton, Pollyea, Daniel A.

“…Venetoclax is approved for older untreated acute myeloid leukemia (AML) patients. Venetoclax was available prior to approval off-label. We assessed our…”
Get full text

Effect of high-dose plerixafor on CD34 + cell mobilization in healthy stem cell donors: results of a randomized crossover trial by Pantin, Jeremy, Purev, Enkhtsetseg, Tian, Xin, Cook, Lisa, Donohue-Jerussi, Theresa, Cho, Elena, Reger, Robert, Hsieh, Matthew, Khuu, Hanh, Calandra, Gary, Geller, Nancy L, Childs, Richard W

“…Hematopoietic stem cells can be mobilized from healthy donors using single-agent plerixafor without granulocyte colony-stimulating factor and, following…”
Get full text

Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib by Nooruddin, Zohra, Miltgen, Nicholas, Wei, Qi, Schowinsky, Jeffrey, Pan, Zengang, Tobin, Jennifer, Purev, Enkhtsetseg, Gutman, Jonathan A, Robinson, William, Pollyea, Daniel A

Get full text

Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant by Sharma, Prashant, Purev, Enkhtsetseg, Haverkos, Bradley, Pollyea, Daniel A., Cherry, Evan, Kamdar, Manali, Mark, Tomer, Forsberg, Peter, Sherbenou, Daniel, Hammes, Andrew, Rabinovitch, Rachel, Smith, Clayton A., Gutman, Jonathan A.

“…We compared outcomes among adult matched related donor (MRD) patients undergoing peripheral blood stem cell transplantation and adult patients undergoing…”
Get full text

Systemic Hypersensitivity to G-CSF in a Healthy Donor Followed By Successful Drug Challenge Allowing Stem Cell Donation by Lee Milligan, Ki, MD, Purev, Enkhtsetseg, MD, Childs, Richard, MD, Milner, Joshua D., MD

“…Distinguishing anaphylaxis from non-IgE mediated systemic reactions after G-CSF may allow selected donors the option for drug challenge to explore safety of…”
Get full text

Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL by Abramson, Jeremy S., Gordon, Leo I., Palomba, Maria Lia, Lunning, Matthew Alexander, Arnason, Jon E., Forero-Torres, Andres, Wang, Michael, Maloney, David G., Sehgal, Alison, Andreadis, Charalambos, Purev, Enkhtsetseg, Solomon, Scott R., Ghosh, Nilanjan, Albertson, Tina M., Xie, Benhuai, Garcia, Jacob, Siddiqi, Tanya

“…Abstract only…”
Get full text

High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model by QINGXIA WEI, CLARKE, Laura, PUREV, Enkhtsetseg, LAVOIE, Jean-Francois, BAJENARU, M. Livia, SHANNON, Patrick, HERLYN, Dorothee, KAPLAN, David, HENKELMAN, R. Mark, GUTMANN, David H, GUHA, Abhijit, SCHEIDENHELM, Danielle K, BAOPING QIAN, TONG, Amanda, SABHA, Nesrin, KARIM, Zia, BOCK, Nicholas A, RETI, Robert, SWOBODA, Rolf

“…High-grade gliomas are devastating brain tumors associated with a mean survival of <50 weeks. Two of the most common genetic changes observed in these tumors…”
Get full text

Identification and functional characterization of an Src homology domain 3 domain‐binding site on Cbl by Sanjay, Archana, Miyazaki, Tsuyoshi, Itzstein, Cecile, Purev, Enkhtsetseg, Horne, William C., Baron, Roland

“…Cbl is an adaptor protein and ubiquitin ligase that binds and is phosphorylated by the nonreceptor tyrosine kinase Src. We previously showed that the primary…”
Get full text

Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia by Purev, Enkhtsetseg, Dumitriu, Bogdan, Hourigan, Christopher S, Young, Neal S, Townsley, Danielle M

“…Abstract We report a case of t(8;21) acute myeloid leukemia presenting as severe aplastic anemia. While initial bone marrow biopsy lacked any cytogenetic…”
Get full text

Protein Phosphatase 2A Associates with Rb2/p130 and Mediates Retinoic Acid-induced Growth Suppression of Ovarian Carcinoma Cells by Vuocolo, Scott, Purev, Enkhtsetseg, Zhang, Dongmei, Bartek, Jiri, Hansen, Klaus, Soprano, Dianne Robert, Soprano, Kenneth J.

“…Levels of Rb2/p130 protein are increased 5–10-fold following all-trans-retinoic acid (ATRA) treatment of the retinoid-sensitive ovarian adenocarcinoma cell…”
Get full text

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study by Abramson, Jeremy S, Palomba, M Lia, Gordon, Leo I, Lunning, Matthew A, Wang, Michael, Arnason, Jon, Mehta, Amitkumar, Purev, Enkhtsetseg, Maloney, David G, Andreadis, Charalambos, Sehgal, Alison, Solomon, Scott R, Ghosh, Nilanjan, Albertson, Tina M, Garcia, Jacob, Kostic, Ana, Mallaney, Mary, Ogasawara, Ken, Newhall, Kathryn, Kim, Yeonhee, Li, Daniel, Siddiqi, Tanya

“…Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety…”
Get full text

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia by Pollyea, Daniel A., Stevens, Brett M., Jones, Courtney L., Winters, Amanda, Pei, Shanshan, Minhajuddin, Mohammad, D’Alessandro, Angelo, Culp-Hill, Rachel, Riemondy, Kent A., Gillen, Austin E., Hesselberth, Jay R., Abbott, Diana, Schatz, Derek, Gutman, Jonathan A., Purev, Enkhtsetseg, Smith, Clayton, Jordan, Craig T.

“…Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Leukemia stem cells (LSCs) drive the initiation and perpetuation of AML, are…”
Get full text

Immunogenicity of recombinant GA733‐2E antigen (CO17‐1A, EGP, KS1‐4, KSA, Ep‐CAM) in gastro‐intestinal carcinoma patients by Staib, Ludger, Birebent, Brigitte, Somasundaram, Rajasekharan, Purev, Enkhtsetseg, Braumüller, Heidi, Leeser, Christian, Küttner, Norbert, Li, Weiping, Zhu, Dawei, Diao, Jun, Wunner, William, Speicher, David, Beger, Hans‐Günther, Song, Hong, Herlyn, Dorothee

“…Targeting the GA733 antigen (also known as CO17‐1A, EGP, KS1‐4, KSA, Ep‐CAM) by monoclonal antibody CO17‐1A or anti‐idiotypic antibodies mimicking the CO17‐1A…”
Get full text

Molecular Determinants of Response to Mosunetuzumab Plus CHOP in Patients with Previously Untreated (1L) Diffuse Large B Cell Lymphoma (DLBCL) by Hamidi, Habib, Kimes, Patrick, Schroeder, Aaron, Uzunovic, Jasmina, Olszewski, Adam J, Sit, Jason, Purev, Enkhtsetseg, Yee, Donald, McCord, Ron

“…Co-lead authors: Habib Hamidi and Patrick Kimes Background: Standard induction therapy cures ~60% of patients (pts) with DLBCL; however, most remaining…”
Get full text

Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy by Colton, Meryl, Purev, Enkhtsetseg, Haverkos, Bradley, Bair, Steven, Jasem, Jagar, Jacob, Allison, Kamdar, Manali

“…•ClonoSEQ, an assay using NGS of the VDJ region from ctDNA, was a sensitive and specific method to monitor patients with relapsed/refractory large B-cell…”
Get full text

Molecular disease monitoring in patients with relapsed/refractory B-cell non-Hodgkin lymphoma receiving anti-CD19 CAR T-cell therapy by Colton, Meryl D., Purev, Enkhtsetseg, Haverkos, Bradley, Bair, Steven Michael, Jasem, Jagar, Schliekelman, Mark Jason, Kamdar, Manali K.

“…7531 Background: Chimeric antigen receptor (CAR) T-cell therapy has improved the historically poor outcomes for relapsed and refractory (R/R) B-cell…”
Get full text

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001 by Abramson, Jeremy S, Palomba, M Lia, Gordon, Leo I, Lunning, Matthew, Wang, Michael, Arnason, Jon, Purev, Enkhtsetseg, Maloney, David G, Andreadis, Charalambos, Sehgal, Alison, Solomon, Scott R, Ghosh, Nilanjan, Dehner, Christine, Kim, Yeonhee, Ogasawara, Ken, Kostic, Ana, Siddiqi, Tanya

“…Lisocabtagene maraleucel (liso-cel) demonstrated significant efficacy with a manageable safety profile as third-line or later treatment for patients with…”
Get full text

Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an "outpatient" alemtuzumab, fludarabine-based reduced intensity allogeneic hematopoietic cell transplantation by Vo, Phuong, Srinivasan, Ramaprasad, Purev, Enkhtsetseg, McDuffee, Emily, Worthy, Tatyana, Shalabi, Reem, Wood, Kristen, Wells, Brian, Reger, Robert, Stroncek, David, Geller, Nancy, Aue, Georg, Tian, Xin, Childs, Richard

Get full text